FLAMADEX AMPOULES 25MG/ML 2ML
FLAMADEX AMPOULES 25MG/ML 2ML - 5PCS
Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
Mechanism of action
Pharmaceutical action: Nonsteroidal anti-inflammatory drug (NSAIDs), a derivative of propionic acid. It has an analgesic, anti-inflammatory and antipyretic effect. The mechanism of action is associated with the inhibition of prostaglandin synthesis at the level of cyclooxygenase-1 and cyclooxygenase-2.
Analgesic effect occurs 30 minutes after parenteral administration. The duration of the analgesic effect after administration at a dose of 50 mg is about 4-8 hours.
When combined with opioid analgesics, dexketoprofen significantly (up to 30-45%) reduces the need for opioids.
Pharmacokinetics: Absorption After intramuscular (IM) administration of dexketoprene, the maximum concentration (Cmax) in blood serum is reached on average after 20 minutes (10-45 minutes). The area under the concentration-time curve (AUC) after a single injection at a dose of 25-50 mg is proportional to the dose, as with the / m, and with intravenous (iv) administration. The corresponding pharmacokinetic parameters are similar after a single and repeated intramuscular or intravenous injection, which indicates the absence of drug accumulation.
Distribution Dexketoprofen is characterized by a high level of plasma protein binding (99%). The average value of Vd is less than 0.25 l / kg, the half-time is about 0.35 hours.
Withdrawal The metabolism of dexketoprofen mainly occurs by conjugation with glucuronic acid, followed by excretion by the kidneys. The elimination half-life (T1 / 2) of dexketoprofen trometamol is about 1-2.7 hours. Pharmacokinetics in special clinical cases In elderly people, an increase in the duration of T1 / 2 is observed (both after a single dose and after repeated i / m ) on average up to 48% and a decrease in the total clearance of the drug.
- relief of pain syndrome of various genesis (including postoperative pain, pain in bone metastases, post-traumatic pain, pain in renal colic, algomenorrhea, sciatica, sciatica, neuralgia, toothache);
- symptomatic treatment of acute and chronic inflammatory, inflammatory-degenerative and metabolic diseases of the musculoskeletal system (including rheumatoid arthritis, osteoarthritis, spondyloarthritis: ankylosing spondylitis, reactive arthritis, psoriatic arthritis).
The drug is intended for symptomatic therapy, reducing pain and inflammation at the time of use, does not affect the progression of the disease.
- Hypersensitivity to dexketoprofen or other NSAIDs or to any of the excipients that make up the drug (including sulfites);
- complete or incomplete combination of bronchial asthma, recurrent nasal polyposis and paranasal sinuses and intolerance to Acetylsalicylic acid or other NSAIDs (including in history);
- erosive and ulcerative lesions of the gastrointestinal tract and duodenum;
- a history of Gastrointestinal bleeding, other active bleeding (including suspected intracranial bleeding), anticoagulant therapy;
- inflammatory bowel disease (ulcerative colitis, Crohn's disease) in the acute stage;
- severe liver dysfunction (10-15 points on the Child-Pugh scale);
- progressive kidney disease, severe renal dysfunction (creatinine clearance less than 30 ml / min);
- confirmed hyperkalemia;
- decompensated heart failure;
- the period after coronary artery bypass surgery;
- hemophilia and other disorders of blood coagulation;
- pregnancy, breastfeeding period;
- children's and teenage age up to 18 years.
Flamadex® is contraindicated for neuroaxial (epidural or intrathecal) administration due to ethanol contained in the preparation.
Peptic ulcer and duodenal ulcer, ulcerative colitis, Crohn's disease, history of liver disease, hepatic porphyria, chronic renal failure (creatinine clearance 30-60 ml / min), chronic heart failure, arterial hypertension, a significant decrease in circulating blood volume (including after surgery), elderly patients (including receiving diuretics, weakened patients and with low body mass), bronchial asthma, concomitant use of glucocorticosteroids (including predniso it), anticoagulants (in t. h. warfarin), antiplatelet agents (in t. h.acetylsalicylic acid, clopidogrel), selective serotonin reuptake inhibitors (including citalopram, Fluoxetine, paroxetine, sertralina), coronary heart disease, cerebrovascular diseases, dyslipidemia / hyperlipidemia, diabetes, peripheral arteries, smoking, a non-smoking room, a non-smoking, unacceptable;, systemic connective tissue diseases, long-term use of nonsteroidal anti-inflammatory drugs, tuberculosis, severe osteoporosis, alcoholism, severe somatic diseases.
Flamadeks® should be used with caution in patients with a history of allergies. Patients with symptoms of gastrointestinal disturbances or with gastrointestinal tract history need medical supervision, especially for gastrointestinal bleeding. In cases of development of gastrointestinal bleeding in patients taking dexketoprofen, the drug is immediately canceled.
It should be carefully prescribed the drug to patients at the same time taking drugs that may increase the risk of ulcers or bleeding: corticosteroids, anticoagulants (for example, warfarin), selective serotonin reuptake inhibitors or antiplatelet agents (including acetylsalicylic acid).
Dexketoprofen can cause reversible inhibition of platelet aggregation and increase bleeding time.
Flamadex® should be carefully prescribed to patients with chronic heart failure I-II functional class according to NYHA.
Similarly to other NSAIDs, Flamadex® can cause an increase in plasma creatinine and nitrogen, have a negative effect on the urinary system, leading to the development of glomerulonephritis, interstitial nephritis, papillary necrosis, nephrotic syndrome and acute renal failure.
As with the use of other NSAIDs, there may be a slight transient increase in the performance of some liver samples, a significant increase in the activity of AST and ALT in blood serum. At the same time, the control of liver and kidney functions is necessary in elderly patients. In the case of a significant increase in the corresponding indicators Flamadex® should be canceled.
Flamadex® should be used with caution in patients with impaired blood formation, patients with systemic lupus erythematosus or other connective tissue diseases.
Like other NSAIDs, Flamadex® can mask the symptoms of infectious diseases. Reported single cases of exacerbation of infectious processes localized in soft tissues with the use of NSAIDs. Therefore, medical supervision of patients with signs of bacterial infection or deterioration during dexketoprofen treatment is required.
Caution should be exercised in the appointment of the drug to patients with impaired liver, kidney, heart, or with conditions that may cause fluid retention in the body. In these patients, the use of NSAIDs can lead to deterioration and fluid retention in the body.Care must also be taken when prescribing dexketoprofen to patients using diuretics or susceptible to hypovolemia, since they increase the risk of nephrotoxicity.
Caution is necessary when prescribing the drug to elderly people, since they more often detect impaired renal function, liver or cardiovascular system, as well as the occurrence of undesirable reactions, such as gastrointestinal bleeding or intestinal perforation.
Each ampoule of Flamadex® contains 200 mg of ethanol.
Influence on the ability to drive vehicles and other mechanisms that require high concentration of attention
In connection with possible dizziness and drowsiness during treatment with Flamadex®, the ability to concentrate and the speed of psychomotor reactions may decrease.
Solution for intravenous and intramuscular administration of 25 mg / ml.
On 2 ml in ampoules of light-protective glass with a color ring of a break or with a color point and a notch. One, two or three color rings and / or two-dimensional bar code, and / or alphanumeric coding with or without additional color rings, two-dimensional bar code, alpha-numeric coding are additionally applied to the ampoules.
On 5 ampoules in a blister strip packaging from a film of polyvinyl chloride and aluminum foil or polymer film, or without foil and film.
1 or 2 blister strip packagings together with the application instruction in a pack from a cardboard.
In the dark place at a temperature of no higher than 25 ° C. Keep out of reach of children.
2 years. Do not use beyond the expiration date printed on the package.
1 amp (2 ml):
- dexketoprofen trometamol (in terms of dexketoprofen) 50 mg
Excipients: ethanol (95% ethyl alcohol based on 100% substance) 200 mg, sodium chloride 8 mg, sodium disulfite 2 mg, sodium hydroxide to pH 6.5-8.5, water for injection to 2 ml
Description: a clear, colorless solution.
Intramuscularly (deeply, slowly), intravenously in a jet (slowly at least 15 seconds) or drip (10-30 minutes).
Recommended dose for adults: 50 mg every 8-12 hours. If necessary, repeated administration of the drug with a 6-hour interval is possible. The daily dose should not exceed 150 mg. Flamadex® is indicated for short-term use, and treatment should be limited to a period of acute symptoms (no more than 2 days).
In patients with mild and moderately impaired liver function (5–9 points on the Child-Pugh scale), the total daily dose should be reduced to 50 mg and frequent monitoring of the functional parameters of the liver should be carried out. Flamadeks® should not be prescribed to patients with severely impaired liver function.
Impaired renal function.
For patients with mild renal impairment (creatinine clearance - 30-60 ml / min), the daily dose is reduced to 50 mg. Flamadex® should not be prescribed to patients with moderately severe or severe renal insufficiency (creatinine clearance less than 30 ml / min).
Dose adjustment for elderly patients is usually not required, however, due to the physiological decline in renal function, it is recommended to reduce the dose of the drug: the total daily dose of 50 mg for lung disorders of renal function in elderly patients.
Rules for the preparation of solutions.
To prepare the Flamadex® solution for intravenous infusion, the contents of one ampoule (2 ml) are diluted in 30-100 ml of a 0.9% solution of sodium chloride, glucose solution or Ringer's solution. The solution should be prepared under aseptic conditions, protected from exposure to daylight. The prepared solution should be clear and colorless.
The incidence of side effects: often (1-10%), infrequently (0.1-1%), rarely (0.01-0.1%), very rarely (less than 0.01%, including individual messages).
From the hematopoietic system: rarely - anemia; very rarely - neutropenia, thrombocytopenia.
From the side of the central nervous system: infrequently - headache, dizziness, insomnia, drowsiness; rarely - paresthesia.
From the senses: infrequently - blurred vision; rarely tinnitus.
Since the cardiovascular system: infrequently - arterial hypotension, feeling of heat, hyperemia of the skin; rarely - extrasystole, tachycardia, arterial hypertension, peripheral edema, superficial thrombophlebitis.
On the part of the respiratory system: rarely - bradypnea; very rarely - bronchospasm, dyspnea.
On the part of the digestive system: often - nausea,vomiting; infrequently - abdominal pain, dyspepsia, diarrhea, constipation, hematemesis, dry mouth; rarely, erosive-ulcerative lesions of the gastrointestinal tract (GIT), including bleeding and perforation, anorexia, increased activity of liver enzymes, jaundice; very rarely - damage to the pancreas, liver damage.
From the urinary system: rarely - polyuria, renal colic; very rarely - nephritis or nephrotic syndrome.
Reproductive system: rarely - in women - menstrual disorders, in men - dysfunction of the prostate gland.
On the part of the musculoskeletal system: rarely - muscle spasm, difficulty in movements in the joints.
Dermatological reactions: sometimes - dermatitis, rash, sweating; rarely acne; very rarely - photosensitivity.
Allergic reactions: rarely - urticaria; very rarely - severe skin reactions (Stevens-Johnson syndrome, Lyell's syndrome), angioedema, allergic dermatitis.
Metabolism: rarely - hyperglycemia, hypoglycemia, hypertriglyceridemia.
From the laboratory indicators: rarely - ketonuria, proteinuria.
Local and general reactions: often - pain at the injection site; infrequently - inflammatory reaction, hematoma, hemorrhages at the injection site, feeling hot, chills, fatigue; rarely back pain, fainting, fever; very rarely - anaphylactic shock, swelling of the face
Others: aseptic meningitis, occurring mainly in patients with systemic lupus erythematosus or mixed connective tissue diseases, hematological disorders (purpura, aplastic and hemolytic anemia, rarely agranulocytosis and bone marrow hypoplasia).